Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peifekang
- Development stage
- Unknown
- Lead developer
- Sine Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Peifekang is a live multi-strain probiotic formulation containing *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. It is primarily used to regulate gut microbiota and treat gastrointestinal disorders such as diarrhea, constipation, and abdominal distension. In clinical research, it is being investigated for its potential to improve metabolic parameters and hormonal balance in women with polycystic ovary syndrome (PCOS) when used as an adjunct to oral contraceptives. The mechanism involves restoring intestinal flora balance, which may influence systemic inflammation and insulin sensitivity through the gut-microbiota-hormone axis.
- Brand names
- PeifekangBIFICO
- Other names
- Triple Live BacteriaBifidobacterium longum + Lactobacillus acidophilus + Enterococcus faecalis
Beyond the preview
Go deeper on Peifekang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peifekang.